Skip to main content

Table 3 The polymorphisms of XPD and the risk of HCC

From: XPD codon 312 and 751 polymorphisms, and AFB1 exposure, and hepatocellular carcinoma risk

 

Controls

HCCs

   

XPD genotype

n

%

n

%

OR (95% CI)

Adjusted OR (95% CI)a

P trend

XPD codon Asp312Asn

   DDb

453

63.6

364

58.9

Reference

Reference

 

   DNb

200

28.1

190

30.7

1.18(0.92-1.51)

1.12(0.83-1.51)

0.460

   NNb

59

8.3

64

10.4

1.35(0.93-1.97)

0.89(0.56-1.41)

0.620

XPD codon Lys751Gln

   LLc

464

65.2

272

44.0

Reference

Reference

 

   LGc

187

26.3

222

35.9

2.03(1.58-2.59)

1.75(1.30-2.37)

< 0.001

   GGc

61

8.6

124

20.1

3.47(2.47-4.88)

2.47(1.62-3.76)

< 0.001

  1. a Adjusted for age, sex, ethnicity, HBsAg, anti-HCV, AFB1-exposure years, and AFB1-DNA adduct levels.
  2. b DD, DN, and NN represented the homozygotes of XPD codon 312 Asp alleles, the heterozygotes of XPD codon 312 Asp and Asn allele, and the homozygotes of XPD codon 312 Asn alleles, respectively.
  3. c LL, LG, and GG represented the homozygotes of XPD codon 751 Lys alleles, the heterozygotes of XPD codon 751 Lys and Gln allele, and the homozygotes of XPD codon 751 Gln alleles, respectively.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us